Drug intelligence / Profile preview

miR-484 mimic

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intraperitoneal, Intratumoral, Intravenous
01

Overview

miR-484 mimic is a synthetic, double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-484 (miR-484). It is primarily utilized as a research-use-only laboratory tool to investigate the functional roles of miR-484 in various biological processes and diseases, particularly in oncology and ischemic injuries. miR-484 acts as a post-transcriptional regulator by binding to the 3'-untranslated region (3'-UTR) of target mRNAs, leading to translational repression or mRNA degradation. Key validated targets of miR-484 include HOXA5, BCL2L13, YAP1, PECAM1, PSMG1, CDA, VEGFB, and VEGFR2. Depending on the cellular context and cancer type, miR-484 can act as either an oncogene (e.g., in triple-negative breast cancer, cervical cancer, and prostate cancer) or a tumor suppressor (e.g., in gastric cancer and ovarian cancer).

Other names
hsa-miR-484 agomirhsa-miR484 agomirhsa-miR 484 agomirhsa-miR-484 mimichsa-miR484 mimichsa-miR 484 mimicmiR-484 agomirmiR484 agomirmiR 484 agomirmicroRNA-484 mimicmicroRNA484 mimicmicroRNA 484 mimic
02

Targets

BCL2L13HOX (HOX transcription factor family)VEGFB (Vascular endothelial growth factor B)TEAD (TEAD family)Kinase insert domain receptor messenger RNAPECAM1 (PECAM-1)DUSP2 (Proteasome assembly chaperone 1)

Beyond the preview

Go deeper on miR-484 mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-484 mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call